MAP2K7 and melanoma: Irrespective of prior treatment with MEK inhibitors or BRAF inhibitor, a recent phase I clinical study demonstrates that vemurafenib, carboplatin, and paclitaxel combination chemotherapy is more effective and tolerable in patients with advanced melanoma with B-RAFV600E mutant protein53.